Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by LithLoveron Oct 14, 2022 10:08am
172 Views
Post# 35024563

Grail even less accurate than previously thought

Grail even less accurate than previously thoughtGrail test found to have even more false positives than before. Imagine taking the test being told you have cancer and than finding out the test was only 38% accurate.  

29.8% of the participants with false alarms underwent invasive procedures

Sept 12, 2022

https://www.medtechdive.com/news/amid-merger-turmoil-illuminas-grail-unit-reports-downturn-in-accuracy-of/631583/

  • Updated data on Grail’s multi-cancer early detection blood test Galleri suggest the diagnostic is less accurate than previously thought. 
  • Last year, Grail reported that 44.6% of patients with positive test results actually had cancer. In the latest analysis, the figure, known as the positive predictive value, has fallen to 38.0%.
  • News of the falling predictive power seen in the study, which used an old version of Galleri, comes amid growing doubts about the fate of the Illumina-Grail merger, which the European Commission has blocked.


<< Previous
Bullboard Posts
Next >>